Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Biomedical Innovation topic
No spam. Unsubscribe anytime.
Entrepreneurs pitch limited access to experimental treatments as an economic and patient‑care opportunity
Summary
Supporters of HB1735 told the committee the bill would permit narrowly defined access to investigational or early‑phase treatments for patients with serious conditions and could attract biotech founders and clinics to New Hampshire; supporters framed the bill as patient choice with oversight; opponents were not prominent in the transcript.
Proponents of HB1735 presented it as a narrowly tailored bill to allow authorized access to investigational treatments—generally products that have completed early safety (phase 1) testing and are provided under clinical oversight—for patients with serious or chronic conditions who lack effective alternatives. Entrepreneurs and prospective clinic developers said the measure would let patients access promising care within New Hampshire under state oversight and could attract biotech founders and operators to the state.
Supporters emphasized consent, clinical oversight and data collection, and argued the alternative—patients traveling abroad for unregulated care—already happens. Proponents also cast the bill as an economic development opportunity: start‑ups, small clinic operators and their supply chains would create jobs, and a modest number of firms choosing New Hampshire could have an outsized local effect.
Committee members asked about safety, regulatory overlap with the FDA, and proposed guardrails. Supporters said the bill would not bypass federal rules and that it would limit activity to interventions meeting specified safety thresholds and physician oversight.
What happens next: the committee asked for clarifying language about scope, foreign founders and oversight, and noted the need to ensure state rules align with federal law and licensing requirements.
